Here, the GA2LEN ANACARE centers of reference and excellence for anaphylaxis and food allergy outline our consensus statement on the use of omalizumab for treating IgE‐mediated food allergy, acknowledging its existing licenses for other allergic diseases and its recent approval for IgE‐mediated food allergy by the US Food & Drug Administration (FDA). Here, IGHE is linked to anaphylaxis.